{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:25:29Z","timestamp":1787030729374,"version":"build-2736575974"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Dalpiciclib shows satisfactory efficacy and safety in patients with hormone receptor-positive (HR\n                      <jats:sup>+<\/jats:sup>\n                      )\/human epidermal growth factor receptor 2-negative (HER2\n                      <jats:sup>-<\/jats:sup>\n                      ) advanced breast cancer. Nevertheless, relevant real-world evidence is inadequate, particularly in elderly patients. This real-world study intended to explore the efficacy and safety of dalpiciclib plus endocrine therapy in elderly patients with HR\n                      <jats:sup>+<\/jats:sup>\n                      \/HER2\n                      <jats:sup>-<\/jats:sup>\n                      advanced breast cancer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This single-center retrospective study analyzed the data of 70 elderly patients (\u226565 years) with HR\n                      <jats:sup>+<\/jats:sup>\n                      \/HER2\n                      <jats:sup>-<\/jats:sup>\n                      advanced breast cancer receiving dalpiciclib combined with endocrine therapy. The median (range) follow-up duration was 13.5 (1.7-29.4) months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The objective response rate (ORR) was 14.3%, and the disease control rate was 94.3%. The ORR was higher in patients with first-line dalpiciclib-based therapy than in those with second-line therapy or above (24.4% vs. 0.0%) (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.004). A total of 39 (55.7%) progression-free survival (PFS) events were recorded. The median (95% confidence interval) PFS was 17.0 (14.6-19.4) months after dalpiciclib plus endocrine therapy. The multivariate Cox regression model disclosed that Eastern Cooperative Oncology Group performance status score 2 (vs. 0) [hazard ratio (HR): 4.010,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.028], lines of dalpiciclib-based therapy (HR: 4.161,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.041), cross-line dalpiciclib (HR: 3.362,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.046), and endocrine resistance (HR: 2.728,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.047) were associated with shorter PFS. The most common adverse events were leukopenia (97.1%) and neutropenia (95.7%), which were predominantly grade 2 or 3. Grade 4 adverse events included leukopenia (2.9%), neutropenia (7.1%), and thrombopenia (1.4%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Dalpiciclib plus endocrine therapy possesses acceptable efficacy and safety for the treatment of elderly patients with HR\n                      <jats:sup>+<\/jats:sup>\n                      \/HER2\n                      <jats:sup>-<\/jats:sup>\n                      advanced breast cancer.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1789316","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:29:15Z","timestamp":1787027355000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of dalpiciclib combined with endocrine therapy in elderly patients with HR+\/HER2- advanced breast cancer: a real-world study"],"prefix":"10.3389","volume":"16","author":[{"given":"Yan","family":"Li","sequence":"first","affiliation":[{"name":"Department of Breast Medicine, The Affiliated Tumor Hospital, Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Breast Medicine, The Affiliated Tumor Hospital, Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Breast Medicine, The Affiliated Tumor Hospital, Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Breast Medicine, The Affiliated Tumor Hospital, Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Breast Medicine, The Affiliated Tumor Hospital, Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhui","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Breast Medicine, The Affiliated Tumor Hospital, Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiner","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Medicine, The Affiliated Tumor Hospital, Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Breast Medicine, The Affiliated Tumor Hospital, Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21863","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA: A Cancer J For Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2021.05.007","article-title":"Breast cancer in women over 65 years- a review of screening and treatment options","volume":"37","author":"Desai","year":"2021","journal-title":"Clin Geriatr Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00935-6","article-title":"Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer","volume":"21","author":"Lloyd","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104351","article-title":"Recent strategies to overcome breast cancer resistance","volume":"197","author":"Khan","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"6012","DOI":"10.3390\/jcm12186012","article-title":"The treatment landscape of elderly patients with hormone receptor-positive Her2 negative advanced breast cancer: current perspectives and future directions","volume":"12","author":"Laface","year":"2023","journal-title":"J Clin Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1159\/000513708","article-title":"Adjuvant treatment of elderly breast cancer patients: offer the best chances of cure","volume":"17","author":"Marinopoulos","year":"2022","journal-title":"Breast Care (Basel)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00228-0","article-title":"Dalpiciclib in advanced breast cancer","volume":"24","author":"Chen","year":"2023","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S529794","article-title":"Advancements in dalpiciclib for the treatment of breast cancer patients: a review","volume":"17","author":"Chen","year":"2025","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13957","article-title":"Preclinical characterization of SHR6390, a novel CDK 4\/6 inhibitor, in vitro and in human tumor xenograft models","volume":"110","author":"Long","year":"2019","journal-title":"Cancer Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01562-9","article-title":"Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial","volume":"27","author":"Xu","year":"2021","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00172-9","article-title":"Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"24","author":"Zhang","year":"2023","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"103756","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112152-20220825-00578","article-title":"Expert consensus on the management of adverse events of CDK4\/6 inhibitors in breast cancer","volume":"44","author":"Ge","year":"2022","journal-title":"J Chin J Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","article-title":"The CDK4\/6 inhibitor revolution - a game-changing era for breast cancer treatment","volume":"21","author":"Morrison","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2174\/1389557522666220606095540","article-title":"Cyclin-dependent kinase 4\/6 inhibitors against breast cancer","volume":"23","author":"Hassan","year":"2023","journal-title":"Mini-Rev Med Chem"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241302018","article-title":"Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+\/HER2-metastatic breast cancer patients: a multicenter study (YOUNGBC-28)","volume":"16","author":"Chen","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinsp.2023.100291","article-title":"Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer","volume":"78","author":"Liu","year":"2024","journal-title":"Clinics (Sao Paulo Brazil)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-024-01575-5","article-title":"Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study","volume":"31","author":"Yoshinami","year":"2024","journal-title":"Breast Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35296","article-title":"Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive\/HER2-negative metastatic breast cancer with real-world data from the OPAL registry","volume":"156","author":"Thill","year":"2025","journal-title":"Int J Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.3390\/diagnostics13111938","article-title":"Real-world outcomes of CDK4\/6 inhibitors treatment in metastatic breast cancer in Romania","volume":"13","author":"Miron","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2025.03.003","article-title":"Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive\/HER2-negative metastatic breast cancer: Turkish Oncology Group (TOG) study","volume":"25","author":"Kahraman","year":"2025","journal-title":"Clin Breast Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105570","article-title":"Real-world progression-free survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR-positive\/HER2-negative metastatic breast cancer in United States routine clinical practice","volume":"10","author":"Rugo","year":"2025","journal-title":"ESMO Open"},{"key":"B27","doi-asserted-by":"publisher","first-page":"5164","DOI":"10.3390\/cancers15215164","article-title":"Clinical impact of CDK4\/6 inhibitors in de novo or PR- or very elderly post-menopausal ER+\/HER2- advanced breast cancers","volume":"15","author":"Tang","year":"2023","journal-title":"Cancers"},{"key":"B28","doi-asserted-by":"publisher","first-page":"7441","DOI":"10.3390\/jcm13237441","article-title":"Standard versus reduced CDK4\/6 inhibitor therapy in elderly patients with metastatic hormone receptor-positive, HER2-negative breast cancer: an observational multicenter study","volume":"13","author":"Fedele","year":"2024","journal-title":"J Clin Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1186\/s12885-024-13357-5","article-title":"Activity of CDK4\/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study","volume":"24","author":"Kahraman","year":"2024","journal-title":"BMC Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.143","article-title":"Beyond clinical trials: CDK4\/6 inhibitor efficacy predictors and nomogram model from real-world evidence in metastatic breast cancer","volume":"3","author":"Liu","year":"2024","journal-title":"Cancer Innov"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2022.100859","article-title":"Palbociclib and letrozole in hormone-receptor positive advanced breast cancer: predictive response and prognostic factors","volume":"46","author":"Gharib","year":"2022","journal-title":"Curr Probl Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000527917","article-title":"CDK4\/6 inhibitors in advanced HR+\/HER2 - breast cancer: a multicenter real-world data analysis","volume":"18","author":"Muller","year":"2023","journal-title":"Breast Care (Basel)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/jco-24-02086","article-title":"Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 inhibition: results from the phase III postMONARCH trial","volume":"43","author":"Kalinsky","year":"2025","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","article-title":"Overcoming endocrine resistance in breast cancer","volume":"37","author":"Hanker","year":"2020","journal-title":"Cancer Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3390\/jcm14041071","article-title":"Evaluation of dose reduction factors and impact on progression-free survival in patients treated with CDK 4\/6 inhibitors","volume":"14","author":"G\u00fcren","year":"2025","journal-title":"J Clin Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102924","article-title":"Post-progression treatment options after CDK4\/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer","volume":"135","author":"Sahin","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2025.2593540","article-title":"Post-CDK4\/6 inhibitor treatment landscape in metastatic hormone receptor-positive breast cancer: a narrative review","volume":"26","author":"G\u00fcren","year":"2026","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1789316\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:29:18Z","timestamp":1787027358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1789316\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":37,"alternative-id":["10.3389\/fonc.2026.1789316"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1789316","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"1789316"}}